BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the findings from a long-term (104-week) post-hoc analysis of pooled data from the PALACE phase III clinical trial program of Otezla® (apremilast) will be presented at the European League Against Rheumatism (EULAR) Annual Congress in Rome, Italy. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4) approved for the treatment of adults with active psoriatic arthritis.
Help employers find you! Check out all the jobs and post your resume.
